TWM
REGN icon

TRB Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

TRB Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$206K Hold
330
– – 0.03% 278
2026
Q1 		$255K Buy
+330
New +$253K 0.04% 229

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

TRB Wealth Management's REGN Position: Q2 2026 in Review

TRB Wealth Management held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 330 shares worth $206K. The position accounts for 0.03% of the portfolio, ranked #278.

TRB Wealth Management first reported a position in REGN in Q1 2026 and has held it in 2 quarters since. The position peaked at $255K in Q1 2026. 1,326 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • TRB Wealth Management held 330 shares of Regeneron Pharmaceuticals worth $206K as of Q2 2026.
  • TRB Wealth Management left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up 0.03% of TRB Wealth Management's portfolio in Q2 2026, its #278 holding.
  • TRB Wealth Management first reported a position in Regeneron Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • TRB Wealth Management's Regeneron Pharmaceuticals position peaked at $255K in Q1 2026.
  • 1,326 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on TRB Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.